OptimizeRx Corp 10-K

Item 8. Financial Statements and Supplementary Data Index to Financial Statements Required by Article 8 of Regulation S-X: Audited Financial Statements: F-1 Report of Independent Registered Public Accounting Firm; F-4 Consolidated Balance Sheets as of December 31, 2024 and 2023; F-5 Consolidated Statements of Operations for the Years Ended December 31, 2024 and 2023; F-6 Consolidated Statement of Stockholders’ Equity for the Year Ended December 31, 2024; F-7 Consolidated Statement of Stockholders’ Equity for the Year Ended December 31, 2023; F-8 Consolidated Statements of Cash Flows for the Years Ended December 31, 2024 and 2023; and F-9 Notes to Consolidated Financial Statements 31 Report of Independent Registered Public Accounting Firm To the Stockholders and Board of Directors of OptimizeRx Corporation Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of OptimizeRx Corporation and Subsidiaries (the “Company”) as of December 31, 2024 and 2023, and the related consolidated statements of operations, stockholders’ equity and cash flows for the years then ended, and the related notes (collectively referred to as the consolidated financial statements). In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United Sates of America. Basis for Opinion These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. Critical Audit Matters The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they related. F- 1 To the Stockholders and Board of Directors of OptimizeRx Corporation Page Two Critical Audit Matter - Revenue Recognition As disclosed in Note 2 to the consolidated financial statements, the Company recognizes revenue upon transfer of control of promised products or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products or services. The principal considerations for our determination that performing procedures relating to revenue recognition is a critical audit matter is that significant judgment is exercised in determining revenue recognition for customer agreements and includes the following: (1) determining whether services are considered distinct performance obligations that should be accounted for separately versus together, (2) the pattern and timing of delivery for each distinct performance obligation, and (3) identification and treatment of contract terms that may impact the timing and amount of revenue recognized. How the Critical Audit Matter Was Addressed in the Audit The audit procedures we performed to address this critical audit matter included the following: (1) obtaining an understanding of the design and implementation of controls related to identifying distinct performance obligations, determining the timing of revenue recognition, and estimating any variable consideration, (2) selecting of a sample of customer agreements and testing management’s identification and treatment of contract terms, (3) testing the mathematical accuracy of management’s calculations of revenue and the associated timing of revenue recognized in the consolidated financial statements, (4) confirming data utilized to recognize revenue with third-party service providers to ensure completeness and accuracy of the data used to recognize revenue, and (5) confirming with the Company’s customers the contract terms and conditions of agreements and completion of the Company’s performance obligations under the contract. Critical Audit Matter – Valuation of Goodwill As discussed in Notes 2 and 7 to the consolidated financial statements, the Company evaluates goodwill for impairment on an annual basis as of December 31 or more frequently if events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. The goodwill balance as of December 31, 2024, was $70.9 million. The Company’s goodwill impairment assessment involves comparing the fair value of each reporting unit to its carrying value. The Company estimates the fair value of its reporting units using a weighting of fair values derived from the income and market approaches. The determination of fair value using the income approach is based on the present value of estimated future cash flows, which requires management to make significant estimates and assumptions of revenue growth rates and operating margins, and selection of the discount rate. The determination of the fair value using the market approach requires management to make significant assumptions related to market multiples of earnings derived from comparable publicly traded companies with similar operating and investment characteristics as the reporting unit. During the quarter ended September 30, 2024, the Company identified circumstances that would be indicative of possible impairment and recorded impairment expense of $7.5 million. Based on the results of the Company’s annual impairment testing as of December 31, 2024, no impairment was recognized as the fair value of the Company’s reporting units exceeded their carrying value. We identified the Company’s goodwill impairment assessments as a critical audit matter because of the significant estimates and assumptions used by management to estimate the fair value of the reporting unit. This required a high degree of auditor judgment and an increased extent of effort, including the need to involve our fair value specialists, when performing audit procedures to evaluate the reasonableness of management’s estimates and assumptions of future cash flows based on estimates of revenue growth rates and gross profit margins and selection of the discount rate for the income approach, and multiples of earnings for the market approach. F- 2 To the Stockholders and Board of Directors of OptimizeRx Corporation Page Three How the Critical Audit Matter Was Addressed in the Audit Our audit procedures related to the Company’s goodwill impairment assessments included the following, among others: (1) Obtaining an understanding of the design and implementation of controls relating to management’s assessment of goodwill for potential impairment, including management’s controls over forecasts of future cash flows based upon estimates of revenue growth rates and operating margins and the selection of the discount rate for the income approach, and determination of multiples of earnings for the market approach. (2) We evaluated the reasonableness of management’s forecasts of future cash flows based on revenue growth rates and operating margins by comparing the forecasts to historical revenues and operating margins. We performed procedures to verify the mathematical accuracy of the calculations used by management. Furthermore, we assessed the appropriateness of the disclosures in the financial statements. (3) With the assistance of our fair value specialists: ● We evaluated the reasonableness of the valuation methodologies. ● We evaluated the reasonableness of the discount rates used in the income approach by developing an independent range of estimated discount rates and comparing that range to the discount rate used in the Company’s valuation. ● We evaluated the multiples of earnings used in the market approach, including testing the underlying source information and mathematical accuracy of the calculations. We have served as the Company’s auditor since 2020. /s/ UHY LLP Sterling Heights, Michigan March 20, 2025 Firm ID # 1195 F- 3 OPTIMIZERx CORPORATION Consolidated Balance Sheets (in thousands, except share and per share data) December 31, 2024 December 31, 2023 ASSETS Current Assets Cash and cash equivalents $ 13,380 $ 13,852 Accounts receivable, net of allowance for credit losses of $ 335 and $ 239 at December 31, 2024 and 2023, respectively 38,212 36,253 Taxes receivable — 1,036 Prepaid expenses and other 2,379 3,190 Total Current Assets 53,971 54,331 Property and equipment, net 150 149 Other Assets Goodwill 70,869 78,357 Patent rights, net 5,517 6,185 Technology assets, net 8,180 9,013 Tradename and customer relationships, net 31,819 34,198 Operating lease right-of-use assets 366 573 Security deposits and other assets 296 568 Total Other Assets 117,047 128,894 TOTAL ASSETS $ 171,168 $ 183,374 LIABILITIES AND STOCKHOLDERS’ EQUITY Current Liabilities Current portion of long-term debt $ 2,000 $ 2,000 Accounts payable – trade 2,156 2,227 Accrued expenses 8,486 7,706 Revenue share payable 5,053 5,506 Taxes payable 318 49 Current portion of lease liabilities 168 222 Deferred revenue 473 172 Total Current Liabilities 18,654 17,882 Non-current Liabilities Long-term debt, net 30,816 34,231 Lease liabilities, net of current portion 209 371 Deferred tax liabilities, net 4,491 4,337 Total Liabilities 54,170 56,821 Commitments and contingencies (See Note 16) Stockholders’ Equity Preferred stock, $ 0.001 par value, 10,000,000 shares authorized, none issued and outstanding at December 31, 2024 and 2023, respectively — — Common stock, $ 0.001 par value, 166,666,667 shares authorized, 20,194,697 and 19,899,679 shares issued at December 31, 2024 and 2023, respectively 20 20 Treasury stock, $ 0.001 par value, 1,741,397 shares purchased at December 31, 2024 and 2023 ( 2 ) ( 2 ) Additional paid-in-capital 201,348 190,793 Accumulated deficit ( 84,368 ) ( 64,258 ) Total Stockholders’ Equity 116,998 126,553 TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 171,168 $ 183,374 The accompanying notes are an integral part of these financial statements. F- 4 OPTIMIZERx CORPORATION Consolidated Statements of Operations (in thousands, except share and per share data) For the Year Ended December 31, 2024 For the Year Ended December 31, 2023 Net revenue $ 92,127 $ 71,522 Cost of revenues, exclusive of depreciation and amortization presented separately below 32,749 28,622 Gross profit 59,378 42,900 Operating Expenses Stock-based compensation 11,467 13,717 Loss on disposal of a business — 2,142 Impairment charges 7,489 6,738 Depreciation and amortization 4,329 2,402 Other sales, general and administrative expenses 49,799 44,303 Total operating expenses 73,084 69,302 Loss from operations ( 13,706 ) ( 26,402 ) Other income (expense) Interest expense ( 6,160 ) ( 1,454 ) Other income 152 500 Interest income 329 2,192 Total other income (expense), net ( 5,679 ) 1,238 Loss before provision for income taxes ( 19,385 ) ( 25,164 ) Income tax (expense) benefit ( 725 ) 7,598 Net loss $ ( 20,110 ) $ ( 17,566 ) Weighted average number of shares outstanding – basic 18,292,935 17,124,801 Weighted average number of shares outstanding – diluted 18,292,935 17,124,801 Loss per share – basic $ ( 1.10 ) $ ( 1.03 ) Loss per share – diluted $ ( 1.10 ) $ ( 1.03 ) The accompanying notes are an integral part of these financial statements. F- 5 OPTIMIZERx CORPORATION Consolidated Statement of Stockholders’ Equity for the Year Ended December 31, 2024 (in thousands, except share and per share data) Additional Common Stock Treasury Stock Paid-in Accumulated Shares Amount Shares Amount Capital Deficit Total Balance, January 1, 2024 19,899,679 $ 20 ( 1,741,397 ) $ ( 2 ) $ 190,793 $ ( 64,258 ) $ 126,553 Stock-based compensation expense Options — — — — 4,783 — 4,783 Restricted stock — — — — 6,683 — 6,683 Issuance of common stock: For restricted stock units vested, net of cancelled units 295,018 — — — ( 911 ) — ( 911 ) Net loss for the year — — — — — ( 20,110 ) ( 20,110 ) Balance, December 31, 2024 20,194,697 $ 20 ( 1,741,397 ) $ ( 2 ) $ 201,348 $ ( 84,368 ) $ 116,998 The accompanying notes are an integral part of these financial statements. F- 6 OPTIMIZERx CORPORATION Consolidated Statement of Stockholders’ Equity for the Year Ended December 31, 2023 (in thousands, except share and per share data) Additional Common Stock Treasury Stock Paid-in Accumulated Shares Amount Shares Amount Capital Deficit Total Balance, January 1, 2023 18,288,571 $ 18 $ ( 1,214,398 ) $ ( 1 ) $ 172,786 $ ( 46,692 ) $ 126,111 Stock-based compensation expense Options — — — — 5,925 — 5,925 Restricted stock — — — — 7,792 — 7,792 Issuance of common stock: For stock options exercised 24,668 — — — 181 — 181 For acquisition 1,444,581 2 — — 12,090 — 12,092 For restricted stock units vested, net of cancelled units 141,859 — — — ( 459 ) — ( 459 ) Repurchase of common stock — — ( 526,999 ) ( 1 ) ( 7,522 ) — ( 7,523 ) Net loss for the year — — — — — ( 17,566 ) ( 17,566 ) Balance, December 31, 2023 19,899,679 $ 20 ( 1,741,397 ) $ ( 2 ) $ 190,793 $ ( 64,258 ) $ 126,553 The accompanying notes are an integral part of these financial statements. F- 7 OPTIMIZERx CORPORATION Consolidated Statements of Cash Flows (in thousands) For the Year Ended December 31, 2024 For the Year Ended December 31, 2023 CASH FLOWS FROM OPERATING ACTIVITIES: Net loss $ ( 20,110 ) $ ( 17,566 ) Adjustments to reconcile net loss to net cash provided by / (used in) operating activities: Depreciation and amortization 4,329 2,402 Impairment charges 7,489 6,738 Loss on disposal of business — 2,142 Bad debt expense 208 666 Stock-based compensation 11,467 13,717 Amortization of debt issuance costs 835 211 Change in: Accounts receivable ( 2,168 ) ( 8,713 ) Prepaid expenses and other assets 811 ( 573 ) Accounts payable ( 72 ) ( 1,320 ) Revenue share payable ( 453 ) 1,515 Accrued expenses and other liabilities 1,053 1,303 Deferred tax liabilities 1,449 ( 7,695 ) Deferred loan fees ( 250 ) — Deferred revenue 301 ( 67 ) NET CASH PROVIDED BY / (USED IN) OPERATING ACTIVITIES 4,889 ( 7,240 ) CASH FLOWS USED IN INVESTING ACTIVITIES: Purchases of property and equipment ( 112 ) ( 87 ) Proceeds from sale of property and equipment — 10 Cash paid for acquisitions, net of cash acquired — ( 82,947 ) Proceeds from sale of business — 2,540 Purchase of short-term investments — ( 162,778 ) Redemptions of short-term investments — 218,709 Capitalized software development costs and other ( 338 ) ( 784 ) NET CASH USED IN INVESTING ACTIVITIES ( 450 ) ( 25,337 ) CASH FLOWS (USED IN) / PROVIDED BY FINANCING ACTIVITIES: Proceeds from long-term debt, net of issuance costs — 37,730 Repayment of long-term debt ( 4,000 ) ( 1,710 ) Repurchase of common stock — ( 7,522 ) Cash paid for employee withholding taxes related to the vesting of restricted stock units ( 911 ) — Proceeds from exercise of stock options, net of cash paid for withholding taxes — ( 278 ) NET CASH (USED IN) / PROVIDED BY FINANCING ACTIVITIES ( 4,911 ) 28,220 NET DECREASE IN CASH AND CASH EQUIVALENTS ( 472 ) ( 4,357 ) CASH AND CASH EQUIVALENTS – BEGINNING OF PERIOD 13,852 18,209 CASH AND CASH EQUIVALENTS – END OF PERIOD $ 13,380 $ 13,852 SUPPLEMENTAL CASH FLOW INFORMATION: Cash paid for interest $ 6,203 $ 1,213 ROU assets obtained in exchange for lease obligations $ — $ 460 Shares issued in connection with acquisition $ — $ 12,091 Cash paid for income taxes $ 161 $ 48 The accompanying notes are an integral part of these financial statements. F- 8 OPTIMIZERx CORPORATION NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (in thousands, excepts share and per share data) NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS OptimizeRx Corporation (the “Company” or “OptimizeRx”) is a digital healthcare technology company that connects over two million HCPs and millions of their patients through an intelligent technology platform embedded within a proprietary omnichannel network. OptimizeRx helps life science organizations engage and support their customers through our combined HCP and DTC marketing strategies. NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates and assumptions have been made in determining the allowance for credit losses, carrying value of assets, fair values assigned to acquired long-lived assets, depreciable and amortizable lives of tangible and intangible assets, the carrying value of liabilities, the valuation allowance for deferred tax assets, the timing of revenue recognition and related revenue-share expenses, and inputs used in the calculation of stock based compensation. Actual results could differ from these estimates. Principles of Consolidation The financial statements reflect the consolidated results of OptimizeRx Corporation, a Nevada corporation, and its wholly owned subsidiaries: Healthy Offers, Inc., a Nevada corporation, and CareSpeak Communications d.o.o., a controlled foreign corporation incorporated in Croatia. Together, these companies are referred to as “OptimizeRx” and “the Company.” All material intercompany transactions have been eliminated. Segment Reporting We operate in one reportable segment and use consolidated net income as its measure of segment profit and loss. Overall, our business involves connecting life science companies to patients and providers. We have a common customer base for all of our solutions, which are primarily all communications with healthcare providers or patients on behalf of life science customers. Our customers are geographically located in the U.S, although we have one (1) technology center located internationally. We do not prepare separate internal income statements by solution as our focus is on selling enterprise arrangements covering multiple solutions that span the entire patient journey with a specific brand. The Company’s chief operating decision maker (“CODM”) is its Chief Executive Officer. The CODM allocates resources and assesses performance of the business and other activities at the operating segment level. The CODM assesses performance for the operating segment and decides how to allocate resources based on net income (loss) that is also reported on the Consolidated Statement of Operations as consolidated net income (loss). The measure of segment assets is reported on the Consolidated Balance Sheets as total assets. The CODM uses consolidated net income (loss) to evaluate income generated in deciding whether to reinvest profits into the segment or to use such profits for other purposes, such as for acquisitions or share repurchases. Consolidated net income (loss) is used to monitor budget versus actual results. The CODM also uses consolidated net income (loss) in competitive analyses by benchmarking to the Company’s competitors. The competitive analysis along with the monitoring of budget versus actual results are used in assessing performance of the segment, and in establishing management and variable compensation. The CODM also regularly reviews the Consolidated Statement of Operations for segment expenses, of which the significant expenses are related to cost of revenues and compensation, including stock-based compensation and other expenses. Since the Company operates as one reportable segment, all required segment financial information is found in the consolidated financial statements and notes to the consolidated financial statements. F- 9 OPTIMIZERx CORPORATION NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (in thousands, excepts share and per share data) Reclassifications Certain items in the previous year financial statements have been reclassified to match the current year presentation. Foreign Currency The Company’s functional currency is the U.S. dollar, however it pays certain expenses related to its two foreign subsidiaries in the local currency, which is the shekel for its subsidiary in Israel and the euro for its Croatian subsidiary. All transactions are recorded at the exchange rate at the time of payment. If there is a time lag between the time of recording the liability and the time of payment, a gain or loss is recorded in the Consolidated Statement of Operations due to any fluctuations in the exchange rate. Cash and Cash Equivalents Cash equivalents include items almost as liquid as cash comprised of investments in AAA rated money market funds that invest in first-tier only securities, which primarily include domestic commercial paper and securities issued or guaranteed by the U.S. government or its agencies. We account for marketable equity securities in accordance with ASC 321-10, “Investments - Equity Securities”, as the shares have a readily determinable fair value quoted on the national stock exchange and are classified within Level 1 of the fair value hierarchy. At December 31, 2024 and 2023, we have recorded $ 8,300 and none , respectively, of money market funds at approximate fair value. Investments We account for marketable securities in accordance with ASC 320, “Investments - Debt Securities”, which require that certain debt securities be classified into one of three categories: held-to-maturity, available-for-sale, or trading securities, and depending upon the classification, value the security at amortized cost or fair market value. Fair Value of Financial Instruments Fair value is defined as the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. The fair value should be calculated based on assumptions that market participants would use in pricing the asset or liability, not on assumptions specific to the entity. In addition, the fair value of liabilities should include consideration of non-performance risk including our own credit risk. In addition to defining fair value, the disclosure requirements around fair value establish a fair value hierarchy for valuation inputs, which is expanded. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels, which is determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are: Level 1 – Inputs are based upon unadjusted quoted prices for identical instruments traded in active markets. Level 2 – Inputs are based upon significant observable inputs other than quoted prices included in Level 1, such as quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. The Company’s stock options and warrants are valued using level 3 inputs. F- 10 OPTIMIZERx CORPORATION NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (in thousands, excepts share and per share data) The Company’s carrying amounts of financial instruments including cash and cash equivalents, accounts receivable, accounts payable, and other current liabilities approximate their fair values due to their short maturities. Accounts Receivable and Allowance for Credit Losses Accounts receivable are reported at realizable value, net of allowances for credit losses, which is estimated and recorded in the period the related revenue is recorded. The Company does not seek collateral to secure its accounts receivable and amounts billed are generally due within a short period of time based on terms and conditions normal for our industry. The Company has a standardized approach to estimate and review the collectability of its receivables based on a number of factors, including the period they have been outstanding. Historical collection and payer reimbursement experience is an integral part of the estimation process related to allowances for credit losses. In addition, the Company regularly assesses the state of its billing operations to identify issues, which may impact the collectability of these receivables or reserve estimates. If current or expected future economic trends, events, or changes in circumstances indicate that specific receivable balances may be impaired, further consideration is given to the collectability of those balances and the allowance is adjusted accordingly. Past-due receivable balances are written off when the Company’s collection efforts have been exhausted. The Company’s customers are primarily large well-capitalized companies, and historically there has been very little bad debt expense. Bad debt expense was $ 208 and $ 666 for the years ended December 31, 2024 and 2023, respectively. The allowance for credit losses was $ 335 and $ 239 as of December 31, 2024 and 2023, respectively. The changes in the allowance for credit losses in each of the years ended December 31, 2024 and 2023, were as follows: 2024 2023 Balance at beginning of year $ 239 $ 352 Bad debt expense 208 666 Write-offs ( 112 ) ( 779 ) Balance at end of year $ 335 $ 239 From time to time, we may record revenue based on our revenue recognition policies described below in advance of being able to invoice the customer. Included in accounts receivable are unbilled amounts of $ 3,241 , and $ 6,077 , at December 31, 2024 and 2023, respectively. Property and Equipment Property and equipment are stated at cost and are being depreciated over their estimated useful lives of three to five years for office equipment and three years for computer equipment using the straight-line method of depreciation for book purposes. Maintenance and repair charges are expensed as incurred. F- 11 OPTIMIZERx CORPORATION NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (in thousands, excepts share and per share data) Leases Lease-related assets, or Operating lease right-of-use (“ROU”) assets, are recognized at the lease commencement date at amounts equal to the respective lease liabilities, adjusted for prepaid lease payments, initial direct costs, and lease incentives received. Lease-related liabilities are recognized at the present value of the remaining contractual fixed lease payments, discounted using our incremental borrowing rate. The Company reviews all options to extend, terminate, or purchase its ROU assets at the commencement of the lease and on an ongoing basis and accounts for these options when they are reasonably certain of being exercised. Operating lease expense is recognized on a straight-line basis over the lease term, while variable lease payments are expensed as incurred. The short-term lease recognition exemption is applied for leases with terms at commencement of not greater than 12 months . Intangible Assets Intangible assets are stated at cost. Finite-lived assets are being amortized over their estimated useful lives of fifteen to seventeen years for patents, eight years for customer relationships, fifteen years for tradenames, two to four years for covenants not to compete, and three to ten years for software and websites, all using the straight-line method. These assets are evaluated when there is a triggering event. Long-lived assets, such as property and equipment and amortizing intangible assets are reviewed whenever events or changes in circumstances indicate that the related carrying amounts may not be recoverable. Impairment of assets with definite-lives is generally determined by comparing projected undiscounted cash flows expected to be generated by the asset, or asset groups, to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted basis, an impairment is recognized to the extent fair value exceeds carrying value. Determining the extent of impairment, if any, typically requires various estimates and assumptions including cash flows directly attributable to the asset, the useful life of the asset and residual value, if any. When necessary, the Company uses internal cash flow estimates, quoted market prices and appraisals, as appropriate, to determine fair value. Actual results could vary from these estimates. In addition, the remaining useful life of the impaired asset is revised, if necessary. We recorded impairment charges of $ 0 and $ 6,738 against the value of our intangible assets during the years ended December 31, 2024 and 2023, respectively. Goodwill Goodwill represents the excess of the purchase price over the fair value assigned to the net tangible and identifiable intangible assets of an acquired business. Goodwill is assessed for impairment at least annually as of December 31, of each year, or more frequently if an event occurs or circumstances change that would reduce the fair value of a reporting unit below its carrying value. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. If we choose to use qualitative factors and determine that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, then the quantitative goodwill impairment test would be required. The goodwill impairment test requires the Company to estimate the fair value of the reporting unit and to compare the fair value of the reporting unit with its carrying amount. F- 12 OPTIMIZERx CORPORATION NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (in thousands, excepts share and per share data) The fair value of a reporting unit is calculated using the income approach (including Discounted Cash Flow (“DCF”)) and validated using a market approach with the involvement of a third-party valuation specialist. The income approach uses expected future cash flows for the reporting unit and discounts those cash flows to present value. Expected future cash flows are estimated using management assumptions of growth rates, including long-term growth rates, capital expenditures and cost efficiencies. The judgments made in determining the expected future cash flows used to estimate the fair value can materially impact the Company’s financial condition and results of operations. Future acquisitions or divestitures are not included in the expected future cash flows. The Company uses a discount rate based on a calculated weighted average cost of capital which is adjusted for company specific risk premiums. The market approach compares the valuation multiples of similar companies to that of the associated reporting unit. The Company then reconciles the calculated fair values to its market capitalization. The fair value is then compared to its carrying value including goodwill. If the fair value is in excess of its carrying value, the related goodwill is not impaired. If the fair value is less than carrying value, an impairment charge is recognized, equivalent to the amount that the carrying value exceeds the fair value. We recorded impairment charges of $ 7,489 and $ 0 against the value of our goodwill during the years ended December 31, 2024 and 2023, respectively. Revenue Recognition Recognition of revenue requires evidence of a contract, probable collection of proceeds, and completion of substantially all performance obligations. We use a 5-step model to recognize revenue. These steps are: identify the contract with a customer, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize revenue when or as the performance obligations are satisfied. Revenues are primarily generated from content delivery activities in which the Company delivers financial, clinical, or brand messaging through a distribution network of ePrescribers and electronic health record technology providers (channel partners), directly to consumers, or from reselling services that complement the business. This content delivery for a customer is referred to as a program. Unless otherwise specified, revenue is recognized based on the selling price to customers. The Company’s contracts are generally all less than one year and the primary performance obligation is delivery of messages, or our forms of content, but the contract may contain additional services. Additional services may include program design, which is the design of the content delivery program, set up, and reporting. We consider set up and reporting services to be complimentary to the primary performance obligation and recognized through performance of the delivery of content. We consider the design of the programs and related consulting services to be performance obligations separate from the delivery of messages. Performance obligations which are recognized at a point in time upon delivery to the client include the development and delivery of NPI target data lists and custom analytic and consulting projects. The net contract balance for contracts in progress at December 31, 2024 and 2023 was $ 4.3 million and $ 2.0 million, respectively. The outstanding performance obligations are expected to be satisfied during the year ended December 31, 2025. In certain circumstances, the Company will offer sales rebates to customers based on spend volume. Rebates are typically contracted based on a quarterly or annual spend amount based on a volume threshold or tiered model. At the beginning of the year, the rebate percentage is estimated based on input from the sales team and analysis of prior year sales. Thereafter, the open contract balance for the customer is assessed quarterly to ensure the estimated rebate percentage being used for the rebate accrual remains reasonable. The estimated amount of variable consideration will be included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. For the year ended 2024, there were two contracts with customers that included a rebate clause. F- 13 OPTIMIZERx CORPORATION NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (in thousands, excepts share and per share data) As the content is distributed through the platform and network of channel partners (a transaction), these transactions are recorded, and revenue is recognized over time as the distributions occur. Revenue for transactions can be realized based on a price per message, a price per redemption, as a flat fee occurring over a period of time, or upon completion of the program, depending on the client contract. The Company recognizes setup fees that are required for integrating client offerings and campaigns into the rule-based content delivery system and network over the life of the initial program, based either on time, or units delivered, depending upon which is most appropriate in the specific situation. Should a program be cancelled before completion, the balance of set up revenue is recognized at the time of cancellation, as set up fees are nonrefundable. Additionally, the Company also recognizes revenue for providing program performance reporting and maintenance, either by the Company directly delivering reports or by providing access to its online reporting portal that the client can utilize. This reporting revenue is recognized over time as the messages are delivered. Program design, which is the design of the content delivery program, and related consulting services are recognized as services are performed. Disaggregation of Revenue Consistent with ASC Topic 606, we have disaggregated our revenue by timing of revenue recognition. The majority of our revenue is recognized over time as solutions are provided. A small portion of our revenue related to program development, NPI data lists, and other solutions is recognized at a point in time upon delivery to customers. A break down is set forth in the table below. 2024 2023 Revenue recognized over time $ 85,469 $ 63,527 Revenue recognized at a point in time 6,658 7,995 Total Revenue $ 92,127 $ 71,522 In some instances, we license certain of our software applications in arrangements that do not include other performance obligations. In those instances, we record license revenue when the software is delivered for use to the licensee. In instances where our contracts included Software as a Service, the revenue is recognized over the subscription period as services are delivered to the customer. In some instances, the Company also resells messaging solutions that are available through channel partners that are complementary to the HCP marketing business and customer base. These partner specific solutions are frequently similar to our own solutions and revenue recognition for these programs is the same as described above. In instances where the Company sells solutions on a commission basis, net revenue is recognized based on the commission-based revenue split that the Company receives. In instances where the Company resells these messaging solutions and has all financial risk and significant operation input and risk, the Company records the revenue based on the gross amount sold and the amount paid to the channel partner as a cost of sales. The amount of revenue recognized on a net basis was $ 10,999 and $ 3,471 for the years ended December 31, 2024 and 2023, respectively. Cost of Revenues Cost of revenues includes revenue-share expense and costs associated with licensing data from third parties. Cost of revenues does not include depreciation and amortization which is listed separately on the statements of operations. Based on the volume of transactions that are delivered through the channel partner network, the Company provides a revenue-share to compensate the partner, or others, for their promotion of the campaign. Revenue-shares are a negotiated percentage of the transaction fees and can also be specific to special considerations and campaigns. In addition, we pay revenue-share to ConnectiveRx as a result of a 2014 legal settlement in an amount equal to the greater of 10 % of financial messaging distribution revenues generated through our integrated network, or $ 0.37 per financial message distributed through our integrated network. Data acquisition costs consist primarily of the costs to acquire data through flat-fee data licensing agreements. F- 14 OPTIMIZERx CORPORATION NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (in thousands, excepts share and per share data) Change in Accounting Estimate In accordance with its policy, the Company periodically reviews the stand-alone selling prices of its performance obligations under ASC 606 for use in allocating the contract prices. As a result, effective April 1, 2024, the Company updated the methodology for determining the value of program design and consulting services from the residual method to using an adjusted market assessment approach. The effect of this change in estimate was immaterial to the results for the year ended December 31, 2024, but may become material in future periods. Income Taxes Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. Significant judgments are required in order to determine the realizability of these deferred tax assets. In assessing the need for a valuation allowance, the Company evaluates all significant available positive and negative evidence, including historical operating results, estimates of future taxable income and the existence of prudent and feasible tax planning strategies. Changes in the expectations regarding the realization of deferred tax assets could materially impact income tax expense in future periods. The Company recognizes the tax benefit from uncertain tax positions if it is more likely than not that the tax positions will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefit is measured based on the largest benefit that has a greater than 50 % likelihood of being realized upon ultimate settlement. It is the Company’s policy to include interest and penalties related to tax positions as a component of income tax expense. Concentration of Credit Risks The Company maintains its cash and cash equivalents in bank deposit accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts; however, amounts in excess of the federally insured limit may be at risk if the bank experiences financial difficulties. As of December 31, 2024 and 2023, the Company had $ 12,973 and $ 13,261 , respectively, in cash balances in excess of federally insured limits, primarily at Bank of America. Research and Development The Company expenses research and development expenses as incurred. There was no research and development expense for the years ended December 31, 2024 and 2023. Advertising Costs The Company expenses advertising costs as incurred. Advertising costs, included in Other general and administrative expenses were $ 1,049 and $ 776 , for the years ended December 31, 2024 and 2023, respectively. Stock-based Compensation The Company uses the fair value method to account for stock-based compensation. The fair value of the equity instrument is charged directly to compensation expense and additional paid-in capital over the period during which services are rendered. The fair value of each award is estimated on the date of each grant. F- 15 OPTIMIZERx CORPORATION NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (in thousands, excepts share and per share data) For restricted stock awards, the fair value is based on the market value of the Company’s common stock on the date of grant. For market based restricted stock units, the fair value is estimated using a Monte Carlo simulation model. This valuation technique included estimating the movement of stock prices and the effects of volatility, interest rates and dividends. At the year ended December 31, 2024 there are no market based restricted stock units outstanding. For options, fair value is estimated using the Black-Scholes option pricing model that uses the following assumptions. Estimated volatilities are based on the historical volatility of the Company’s common stock over the same period as the expected term of the options. The expected term of options granted represents the period of time that options granted are expected to be outstanding. The Company uses historical data to estimate option exercise behavior and to determine this term. The risk-free rate used is based on the U.S. Treasury yield curve in effect at the time of the grant using a time period equal to the expected option term. The Company has never paid dividends and does not expect to pay any dividends in the future. 2024 2023 Expected dividend yield 0 % 0 % Risk free interest rate 3.52 % - 4.59 % 3.76 % - 4.74 % Expected option term 3.5 years 3.5 years Turnover/forfeiture rate 0 % 0 % Expected volatility 66 % - 72 % 67 % - 72 % Weighted average grant date fair value $ 2.89 $ 6.58 The Black-Scholes option valuation model has limitations on its effectiveness, including that it was developed for use in estimating the fair value of traded options which have no vesting restrictions and are fully transferable and it requires the use of highly subjective assumptions, such as expected stock price volatility. The Company’s stock options have characteristics significantly different from those of traded options, and changes in the subjective input assumptions could materially affect the fair value estimate. Loss Per Common and Common Equivalent Share The computation of basic (loss) earnings per common share is computed using the weighted average number of common shares outstanding during the year. The computation of diluted (loss) earnings per common share is based on the basic weighted average number of shares outstanding during the year plus common stock equivalents, which would arise from the exercise of options and warrants outstanding using the treasury stock method and the average market price per share during the year. The number of common shares potentially issuable upon the exercise of certain awards that were excluded from the diluted loss per common share calculation in 2024 and 2023 was 212,798 and 31,727 related to options, and 78,203 and 52,607 related to restricted stock units, for a total of 291,001 and 84,334 , respectively, because they are anti-dilutive, as a result of the net losses incurred in each of the years ended December 31, 2024 and 2023. F- 16 OPTIMIZERx CORPORATION NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (in thousands, excepts share and per share data) The computation of weighted average shares outstanding and the basic and diluted earnings per common share for the years ended December 31, 2024 and 2023 consisted of the following: Year ended December 31, 2024 Net (Loss) Shares Per Share Amount Basic EPS $ ( 20,110 ) 18,292,935 $ ( 1.10 ) Effect of dilutive securities — — — Diluted EPS $ ( 20,110 ) 18,292,935 $ ( 1.10 ) Year ended December 31, 2023 Net Income Shares Per Share Amount Basic EPS $ ( 17,566 ) 17,124,801 $ ( 1.03 ) Effect of dilutive securities — — — Diluted EPS $ ( 17,566 ) 17,124,801 $ ( 1.03 ) Recently Issued Accounting Guidance ASU Topic 2021-08 Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers , which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers, as if it had originated the contracts. The standard was effective for the Company’s fiscal year beginning January 1, 2023. The adoption of this standard did not have a material effect on our financial position, results of operations, or cash flows. In November 2023, the FASB issued ASU No. 2023-07 (“ASU 2023-07”), Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 requires annual and interim disclosures that are expected to improve reportable segment disclosures, primarily through enhanced disclosures about significant segment expenses. The standard was effective for the Company’s fiscal year beginning January 1, 2024. The requirements of this ASU are disclosure-related and the adoption of this standard did not have a material effect on our financial position, results of operations, or cash flows. Not Yet Adopted In December 2023, the FASB issued ASU No. 2023-09 (“ASU 2023-09”), Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 addresses investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This update also includes certain other amendments to improve the effectiveness of income tax disclosures. The provisions of ASU 2023-09 are effective for annual periods beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the impact of adopting ASU 2023-09. F- 17 OPTIMIZERx CORPORATION NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (in thousands, excepts share and per share data) In November 2024, the FASB issued ASU 2024-03 (“ASU 2024-03”), Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40). ASU 2024-03 requires that public business entities disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The prescribed categories include purchases of inventory, employee compensation, depreciation, intangible asset amortization, and depletion. This authoritative guidance is effective for annual periods beginning after December 15, 2026 and interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the effect of this new guidance on its consolidated financial statements. NOTE 3 - ACQUISITIONS On October 24, 2023, the Company acquired 100 % of the issued and outstanding preferred and common stock of Healthy Offers, Inc., a Nevada corporation d/b/a Medicx Health. Medicx Health is a healthcare consumer-focused omnichannel marketing and analytics company. We completed the acquisition of Medicx Health to enhance and expand the Company’s technology offerings. The acquisition date fair value of consideration transferred was calculated as follows: Net cash transferred $ 83,888 Fair value of common stock transferred 12,091 Fair value of consideration transferred $ 95,979 The goodwill balance reflects the benefits associated with future iterations of the technology platforms, new customer relationships anticipated as a result of the transaction and market participant synergies from economies of scale and is not deductible for tax purposes. In addition, the Company is required to remit, upon collection from the appropriate authorities, approximately $ 1,000 related to certain state and federal income tax receivables which were included on Medicx Health’s balance sheet at the date of acquisition. The Company has recorded $ 1,000 in Taxes receivable, to reflect the receivables due to the Company and $ 1,000 in Accrued expenses, to reflect the total amount due to the former stockholders of Medicx Health. F- 18 OPTIMIZERx CORPORATION NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (in thousands, excepts share and per share data) The following table summarizes the estimated fair value of assets acquired and liabilities assumed at the acquisition date: Assets Acquired Cash $ 941 Accounts receivable 6,028 Taxes receivable 1,036 Prepaid expenses and other 913 Property and equipment 33 Customer relationships intangible 34,000 Trademark and patent intangible 5,700 Technology intangibles 8,300 Operating lease right-of-use assets 145 Deposits 10 57,106 Liabilities Assumed Accounts payable 1,997 Accrued expenses 3,849 Lease liabilities 166 Deferred revenue 75 Deferred tax liabilities 12,033 18,120 Net assets acquired 38,986 Goodwill 56,993 Fair value of consideration transferred $ 95,979 The Company used a third-party valuation specialist to value the intangible assets acquired. The identifiable intangibles are being amortized on a straight line basis over the following estimated useful lives: Customer relationship intangible 15 years Trademark and patent intangible 10 years Technology intangibles 4 to 10 years The Company recognized $ 4,272 of acquisition related costs that were expensed in the current period. These costs are included in the consolidated statement of operations in the line item entitled “Other sales, general and administrative expenses.” The results of operations of Medicx Health have been included in the consolidated statement of operations since the date of acquisition. F- 19 OPTIMIZERx CORPORATION NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (in thousands, excepts share and per share data) The amounts of revenue and net income of Medicx Health included in the Company’s consolidated statement of operations for the period from the acquisition date until December 31, 2023, are as follows: Revenue $ 4,546 Net income 314 The following represents the pro-forma consolidated statement of operations as if Medicx Health had been included in the consolidated results of the Company for the full years ended December 31, 2023: Year ended December 31, Pro-forma consolidated statement of operations 2023 Revenue $ 97,066 Net loss ( 18,616 ) These amounts have been calculated after applying the Company’s accounting policies, adjusting Medicx Health results to reflect the additional amortization that would have been charged assuming the fair value adjustments to intangible assets had been applied on January 1, 2023, full year interest expense associated with the Term Loan and elimination of interest income on short-term investments that were used to fund the acquisition, one time transaction related items, including the amounts incurred by the Company, discussed above and $ 9,600 in transaction related expenses incurred by Medicx Health. During the year ended December 31, 2023, the Company disposed of its non-core Access business - See Item 8. Financials Statements and Supplementary Data; Note 7 - Goodwill and Intangible Assets for additional information regarding this transaction. A pro forma statement of operations for the twelve months ended December 31, 2024 is not presented for this transaction as the pro forma impacts were not material to the Company’s consolidated results. Revenue presented in the pro forma financial consolidated statement of operations data above includes $ 4,169 for the year ended December 31, 2023, to the Access and other non-core solutions for which no revenue was recorded in the year ended December 31, 2024 (see also the discussion under Net Revenues in Results of Operations for the twelve months ended December 31, 2024 in Part I, Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations). NOTE 4 - INVESTMENT SECURITIES There were no investment securities held at December 31, 2024 and 2023. F- 20 OPTIMIZERx CORPORATION NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (in thousands, excepts share and per share data) NOTE 5 – PREPAID EXPENSES Prepaid expenses consisted of the following as of December 31, 2024 and 2023: 2024 2023 Revenue share and exclusivity payments $ 1,213 $ 1,495 Software 397 407 Insurance 239 370 Data 143 513 Other 387 405 Total prepaid expenses $ 2,379 $ 3,190 NOTE 6 – PROPERTY AND EQUIPMENT The Company owned equipment recorded at cost, which consisted of the following as of December 31, 2024 and 2023: 2024 2023 Computer equipment $ 354 $ 266 Furniture and fixtures 54 34 408 300 Less accumulated depreciation 258 151 Property and equipment, net $ 150 $ 149 Depreciation expense was $ 111 and $ 100 for the years ended December 31, 2024 and 2023, respectively. NOTE 7 – GOODWILL AND INTANGIBLE ASSETS Goodwill Our goodwill is related to the acquisitions of Medicx Health in 2023, EvinceMed in 2022, RMDY Health, Inc. in 2019 and CareSpeak Communications in 2018. Goodwill is not amortizable for financial statement purposes. Goodwill is tested for impairment at a reporting segment level at least annually, as of December 31, or on an interim basis if an event occurs or circumstances change (a “Triggering Event”). During the third quarter of 2024, the Company experienced a Triggering Event due to a sustained decline in its stock price and overall market capitalization. Accordingly, the Company conducted a quantitative impairment test of its goodwill at September 30, 2024. The Company estimated the implied fair value of its goodwill using a combination of a market approach and income approach. It was determined that the fair value of the Company’s single reporting unit was less than its carrying value. A noncash charge of $ 7,489 , representing the amount by which the Company’s book value exceeds its estimated fair value, was recorded as a goodwill impairment in the year ended December 31, 2024. F- 21 OPTIMIZERx CORPORATION NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (in thousands, excepts share and per share data) The Company performed the annual goodwill impairment test as of December 31, 2024. The Company performed its annual goodwill impairment test on a quantitative basis for its single reporting unit. In estimating the reporting unit’s fair value, the Company performed a valuation analysis, utilizing a discounted cash flow income approach and a guideline public company market approach. We assigned a probability weighting to each approach of 50 %. The determination of the fair value of the reporting unit requires the Company to make significant estimates and assumptions about the reporting unit’s expected future cash flows. These estimates and assumptions primarily include, but are not limited to, the discount rate, revenue growth rates, operating margins and multiples of earnings. These estimates and assumptions were determined in connection with support from a third-party valuation specialist. The discount rate used is based on the estimated weighted-average cost of capital for companies with profiles similar to our profile and based on an assessment of the risk inherent in those future cash flows. To forecast the reporting unit’s cash flows, the Company takes into consideration economic conditions and trends, historical results and recent performance, estimated future operating results, management’s and a market participant’s view of growth rates, management’s ability to execute on planned future strategic initiatives and anticipates future economic conditions. Macroeconomic factors such as changes in economies, changes in the competitive landscape, changes in government legislation, industry consolidations and other changes beyond the Company’s control could have a positive or negative impact on achieving its targets. Due to the inherent uncertainty involved in making these estimates, actual results could differ from those estimates. In addition, changes in underlying assumptions, especially as they relate to the key assumptions detailed, could have a significant impact on the fair value of the reporting unit. The market approach compares the valuation multiples of similar companies to that of the associated reporting unit. The Company then reconciles the calculated fair values to its market capitalization. After completing testing, it was determined that the fair value of the Company’s single reporting unit was exactly equal to its carrying value and no further impairment to goodwill was recorded for the year ended December 31, 2024. Any amount of negative change to the above disclosed key assumptions could result in future impairment to goodwill. The fair value of any reporting units, used in the annual assessments in 2024 and 2023, is classified as Level 3 measurements within the fair value hierarchy due to significant unobservable inputs, such as discount rates, projections of revenue, cost of revenue and operating expense growth rates, long-term growth rates and income tax rates. Changes in the carrying amount of goodwill on the consolidated balance sheet consist of the following: Balance January 1, 2023 $ 22,674 Acquisitions 56,993 Disposal of business ( 1,310 ) Impairments — Balance January 1, 2024 $ 78,357 Acquisitions — Impairments ( 7,488 ) Balance December 31, 2024 $ 70,869 During the year ended December 31, 2023, we entered into various agreements, including a Product License Agreement and Platform Assets Purchase Agreement, with Mercalis, Inc.(“Mercalis”), collectively the “Transaction”. Under the terms of the Transaction, Mercalis agreed to purchase certain customer contract assets and liabilities related to the Company’s Access and Patient Engagement technologies. In addition, Mercalis was granted a perpetual license to the Access products and a non-exclusive two-year term license to the Patient Engagement products. Total consideration due for the Transaction was $ 3,740 including $ 2,540 related to the Access products. F- 22 OPTIMIZERx CORPORATION NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (in thousands, excepts share and per share data) The Access products portion of the Transaction was deemed to be the disposal of a business for accounting purposes and accordingly the Company recorded a loss on disposal of $ 2,142 including the allocation of a portion of the Company’s goodwill balance of $ 1,310 and the net book value of the underlying technology assets of $ 3,328 . Intangible Assets Intangible assets included on the consolidated balance sheets consist of the following: December 31, 2024 Gross Carrying Amount Accumulated Amortization Net Weighted Average Life Remaining Patent rights $ 7,164 $ 1,647 $ 5,517 7.7 Technology assets 9,711 1,531 8,180 7.5 Other intangible assets Tradename 134 12 122 9.7 Non-compete agreements 1,093 1,093 — — Customer relationships 34,923 3,226 31,697 13.6 Total other 36,150 4,331 31,819 Total intangible assets $ 53,025 $ 7,509 $ 45,516 December 31, 2023 Gross Carrying Amount Accumulated Amortization Net Weighted Average Life Remaining Patent rights $ 7,164 $ 979 $ 6,185 8.8 Technology assets 12,388 3,375 9,013 6.6 Other intangible assets Tradename 134 — 134 10.7 Non-compete agreements 1,093 1,093 — — Customer relationships 34,923 859 34,064 14.6 Total other 36,150 1,952 34,198 Total intangible assets $ 55,702 $ 6,306 $ 49,396 F- 23 OPTIMIZERx CORPORATION NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (in thousands, excepts share and per share data) During the year ended December 31, 2023, we recorded asset impairment charges of $ 6,738 relating to Technology assets patent rights and tradenames that were not considered to be core solutions on a go forward basis, resulting in lower projected revenues for these solutions, as well as the outcome of the disposal of the Access products discussed above. Intangibles are being amortized on a straight-line basis over the following estimated useful lives. Patents 15 – 17 years Tradenames 15 years Non-compete agreements 2 – 4 years Customer relationships 8 years Technology assets 3 – 10 years The Company recorded amortization expense of $ 4,218 and $ 2,302 in the years ended December 31, 2024 and 2023, respectively. Expected future amortization expense of the intangibles assets as of December 31, 2024 is as follows: Year ended December 31, 2025 $ 4,258 2026 4,203 2027 3,906 2028 3,787 2029 3,787 Thereafter 25,575 Total $ 45,516 NOTE 8 – DEFERRED REVENUE The Company has several signed contracts with customers for the distribution of financial messaging, or other services, which include payment in advance. The payments are not recorded as revenue until the revenue is earned under its revenue recognition policy discussed in Note 2. Deferred revenue was $ 473 and $ 172 as of December 31, 2024 and 2023, respectively. These contracts are all short term in nature and all revenue is expected to be recognized within 12 months, or less. Following is a summary of activity in the deferred revenue account for the year ended December 31, 2024. Balance January 1, 2024 $ 172 Revenue recognized ( 18,204 ) Amount collected 18,505 Balance December 31, 2024 $ 473 F- 24 OPTIMIZERx CORPORATION NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (in thousands, excepts share and per share data) Following is a summary of activity in the deferred revenue account for the year ended December 31, 2023. Balance January 1, 2023 $ 164 Revenue recognized ( 12,359 ) Amount collected 12,291 Amount acquired 76 Balance December 31, 2023 $ 172 NOTE 9 – RELATED PARTY TRANSACTIONS During the year ended December 31, 2010, the Company acquired the technical contributions and assignment of all exclusive rights to and for a key patent in process at the time from a former Chief Executive Officer (“CEO”), in exchange for a total payment in shares of common stock and options valued at $ 930 at the time of the acquisition and recorded the patent at that cost. That patent remains in Patents on the consolidated balance sheet as of December 31, 2024. Jim Lang, one of our Board Members, is the CEO of Eversana, a leading global provider of services to the life sciences industry. Eversana is similar to other customers we generate revenue from, such as agencies or resellers. During the years ended December 31, 2024 and 2023, we have recognized $ 375 and $ 336 , respectively, in revenue from contracts engaged with Eversana. These contracts were sourced by Eversana on behalf of life science customers of theirs. The contracts are at market rates and were generated in the normal course of business. William J. Febbo, former Chief Executive Officer of OptimizeRx was appointed to LifeMD’s board of directors during Q2 2023. During the year ended December 31, 2024, there was revenue in the amount of $ 434 from contracts engaged with LifeMD. The contracts were sourced by LifeMD on behalf of their customers and are at market rates and generated in the normal course of business. NOTE 10 – STOCKHOLDERS’ EQUITY Preferred Stock The Company had 10,000,000 shares of preferred stock, $ 0.001 par value per share, authorized as of December 31, 2024. No shares were issued or outstanding in either 2023 or 2024. Common Stock The Company had 166,666,667 shares of common stock, $ 0.001 par value per share, authorized as of December 31, 2024. There were 18,453,300 and 18,158,282 shares of common stock outstanding, net of shares held in treasury, at December 31, 2024 and 2023, respectively. The Company issued 0 shares of common stock and received proceeds of $ 0 in 2024 in connection with the exercise of options under our 2013 Equity Incentive Plan. We issued 24,668 shares of common stock and received proceeds of $ 181 in 2023 in connection with the exercise of options under our 2013 Equity Incentive Plan. The Company issued 295,018 shares of common stock in 2024 and 141,859 shares of common stock in 2023 in connection with the vesting of restricted stock units under our 2013 and 2021 Equity Incentive Plans. See Note 11, Stock Based Compensation. Some of the participants utilized a net withhold settlement method, in which shares were surrendered to cover payroll withholding taxes. Of the shares issued to participants during the year ended December 31, 2024 and 2023, respectively, 101,381 and 42,489 shares, valued at $ 911 and $ 459 , were surrendered and subsequently cancelled. Treasury Stock During the quarter ended March 31, 2023, the Board authorized a share repurchase program, under which the Company could repurchase up to $ 15 million of its outstanding common stock. This stock repurchase authorization expired on March 12, 2024. There were no shares repurchased in 2024 prior to the expiration. During the year ended December 31, 2023, the Company repurchased 526,999 shares of our common stock for a total of $ 7,522 , including commissions paid on repurchases. The repurchased shares were recorded as Treasury Shares using the par value method. F- 25 OPTIMIZERx CORPORATION NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (in thousands, excepts share and per share data) NOTE 11 – STOCK BASED COMPENSATION The Company sponsors two stock-based incentive compensation plans. The first plan is known as the 2013 Incentive Plan (the “2013 Plan”) and was established by the Board of Directors of the Company in June 2013. The 2013 Plan, as amended, authorized the issuance of 3,000,000 shares of Company common stock. The amended plan was approved by shareholders. A total of 234,512 shares of common stock underlying options and 8,000 shares of common stock underlying restricted stock unit awards were outstanding at December 31, 2024. In connection with the adoption of a new plan in 2021, the Company froze the 2013 Plan. At December 31, 2024, there were no shares available for grant under the 2013 Plan. In 2021, the Company adopted a new plan known as the 2021 Equity Incentive Plan (“2021 Plan”). The plan was established by the Board of Directors and approved by shareholders in August 2021. On June 5, 2024, at the 2024 Annual Meeting of Stockholders, the Company’s stockholders approved an amendment to the 2021 Equity Incentive Plan to increase the number of shares of common stock available for awards under the 2021 Equity Incentive Plan by 1,950,000 shares for a total of 4,450,000 shares. A total of 1,611,338 shares of common stock underlying options and 686,326 shares of common stock underlying restricted stock unit awards were outstanding at December 31, 2024. At December 31, 2024, 1,161,064 shares were available for grant under the 2021 Plan. The 2021 Plan allows the Company to grant incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards and other stock-based awards. Incentive stock options may only be granted to persons who are regular full-time employees of the Company at the date of the grant of the option. Non-qualified options may be granted to any person, including, but not limited to, directors, officers, employees and consultants, who the Company’s Board or Compensation Committee determines. The exercise price of options granted under the 2021 Plan must be equal to at least 100 % of the fair market value of our common stock as of the date of the grant of the option. Options granted under the 2021 Plan are exercisable as determined by the Compensation Committee and specified in the applicable award agreement. In no event will an option be exercisable after ten years from the date of grant. Stock Options The compensation cost that has been charged against income related to options for the years ended December 31, 2024 and 2023, was $ 4,783 and $ 5,925 , respectively. No income tax benefit was recognized in the consolidated statements of income and no compensation was capitalized in any of the years presented. During the year ended December 31, 2024, we granted certain performance based options, the expense for which will be recorded over time once the achievement of the performance is deemed probable. There was no expense related to these options recorded during the period. The fair value of these instruments was calculated using the Black-Scholes option pricing model. During 2022, the Company granted certain performance-based stock options, the expense for which will be recorded over time once the achievement of the performance is deemed probable. There was $ 25 in expense related to these options recorded during the year ended December 31, 2024 . The Company had the following option activity during the year ended December 31, 2024 and 2023: Number of Options Weighted average exercise price Weighted average remaining contractual life (years) Aggregate intrinsic value $ Outstanding at January 1, 2023 1,306,870 $ 31.14 Granted 426,703 $ 12.50 Exercised ( 24,668 ) $ 7.34 Expired or forfeited ( 153,844 ) $ 30.70 Outstanding at December 31, 2023 1,555,061 $ 26.38 3.4 $ 1,046 Granted 716,297 $ 5.56 Exercised — $ — Expired or forfeited ( 425,508 ) $ 26.31 Outstanding, December 31, 2024 1,845,850 $ 18.32 3.4 $ 10 Exercisable, December 31, 2024 813,397 $ 30.55 2.2 $ — F- 26 OPTIMIZERx CORPORATION NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (in thousands, excepts share and per share data) The table below reflects information for the total options outstanding at December 31, 2024 Range of Exercise Prices Number of Options Weighted average remaining contractual life (years) Weighted average exercise price $ 4.83 to $ 10.00 780,600 4.7 $ 5.62 $ 10.00 to $ 20.00 674,374 3.0 $ 14.31 $ 20.00 to $ 40.00 105,718 1.2 $ 31.82 $ 40.00 to $ 60.00 185,957 1.6 $ 48.04 $ 60.00 to $ 96.70 99,201 1.7 $ 75.42 Total 1,845,850 3.4 $ 18.32 The table below reflects information for the vested options outstanding at December 31, 2024. Range of Exercise Prices Number of Options Weighted average remaining contractual life (years) Weighted average exercise price $ 4.83 to $ 10.00 47,761 2.8 $ 7.82 $ 10.00 to $ 20.00 403,878 2.8 $ 14.59 $ 20.00 to $ 40.00 98,591 1.2 $ 31.90 $ 40.00 to $ 60.00 165,345 1.5 $ 48.64 $ 60.00 to $ 96.70 97,822 1.7 $ 75.59 Total 813,397 2.2 $ 30.55 A summary of the status of the Company’s non-vested options as of December 31, 2024, and changes during the year ended December 31, 2024, is presented below. Nonvested Options Options Weighted average exercise price Nonvested at January 1, 2024 968,787 $ 22.03 Granted 716,297 $ 5.56 Vested ( 417,740 ) $ 13.46 Forfeited ( 234,981 ) $ 21.80 Nonvested at December 31, 2024 1,032,363 $ 8.69 There is $ 3,651 of expense remaining to be recognized over a period of approximately 2.1 years related to options outstanding at December 31, 2024. F- 27 OPTIMIZERx CORPORATION NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (in thousands, excepts share and per share data) Restricted Stock Units The Company had the following restricted stock unit (“RSU”) activity during the years ended December 31, 2024 and 2023: Number of RSUs Weighted average grant date fair value Weighted average remaining contractual life (years) Outstanding at January 1, 2023 789,074 $ 36.95 Granted 383,406 $ 12.30 Forfeited ( 244,923 ) $ 58.18 Vested and issued ( 141,859 ) $ 31.38 Withheld and cancelled ( 42,489 ) $ 32.47 Outstanding at December 31, 2023 743,209 $ 18.62 1.7 Granted 545,772 $ 7.56 Forfeited ( 198,256 ) $ 17.76 Vested and issued ( 295,018 ) $ 17.84 Withheld and cancelled ( 101,381 ) $ 18.03 Outstanding at December 31, 2024 694,326 $ 10.62 2.1 The Company granted restricted stock units of 545,772 and 383,406 units in 2024 and 2023, respectively, and valued at $ 4,128 and $ 4,715 , respectively. These restricted stock units vest over a period of 1 year to 5 years. The Company recognized expense of $ 6,683 and $ 7,792 in 2024 and 2023, respectively, related to these restricted stock units. A total of $ 5,260 remains to be recognized at December 31, 2024 over a period of 1.88 years. In the year ended December 31, 2024, certain participants utilized a net withhold settlement method, in which shares were surrendered to cover payroll withholding tax. Of the shares issued to participants during the year ended December 31, 2024 and 2023, respectively, 101,381 and 42,489 shares, valued at $ 911 and $ 459 , were surrendered and subsequently cancelled. During 2022, the Company granted certain performance-based restricted stock units, the expense for which will be recorded over time once the achievement of the performance is deemed probable. There was $ 25 in expense related to these restricted stock units recorded during the year ended December 31, 2024 . Non-employee Directors Compensation The director’s compensation program calls for the grant of restricted stock units with a one-year vesting period. The Company granted 50,305 restricted stock units, valued at $ 750 granted to the non-employee directors in 2023. These restricted stock units vested in 2024. The Company granted 64,896 restricted stock units, valued at $ 750 granted to the non-employee directors in 2024 that will vest in 2025, 12 months from the grant dates. Equity Award Modification On April 16, 2023, the Compensation Committee approved a grant to the Company’s then CEO of 86,685 restricted stock units and 161,698 stock options with a grant date fair value of $ 2,500 to vest over a three year period. Concurrently, the then CEO forfeited his October 2021 grant of 182,398 market-based restricted stock units. The forfeiture and accompanying grant was considered an equity modification according to ASC 718, Compensation-Stock Compensation ( “ASC 718”). The additional compensation value created by the termination and issuance of new equity awarded, as measured using a Monte Carlo simulation, was approximately $ 1,900 in total. Under ASC 718 this results in a non-cash expense in current and future periods to be recognized over a three-year period. These expense values are reflected and included in the option and restricted stock expense values discussed above. At December 31, 2024 the remaining expense of $ 1,556 related to the October 2021 grant of market-based restricted stock units was accelerated upon the departure of the CEO. The expense for unvested stock-options and restricted stock units related to the April 2023 grant was reversed. F- 28 OPTIMIZERx CORPORATION NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (in thousands, excepts share and per share data) NOTE 12 – LONG-TERM DEBT Long-term debt consisted of the following at December 31, 2024 and 2023: 2024 2023 Term loan, due in 2027 $ 34,290 $ 38,290 Less: current portion of long-term debt ( 2,000 ) ( 2,000 ) Less: unamortized issuance costs ( 1,474 ) ( 2,059 ) Long-term debt, net $ 30,816 $ 34,231 On October 11, 2023, the Company entered into a Financing Agreement (the “Financing Agreement”) which provided for a term loan (the “Term Loan”) of $ 40 million, the net proceeds of which were used to partially finance the Medicx Health transaction described in Note 3 “Acquisitions”. In connection with the Term Loan the Company incurred issuance costs of approximately $ 2,270 , which were capitalized and are being amortized to interest expense over the life of the Term Loan. Amortization of debt issuance costs for the year ended December 31, 2024 and December 31, 2023 was $ 835 and $ 211 , respectively. The Company’s obligations under the Term Loan are secured by all of the Company’s and its subsidiaries’ assets (including a pledge of all of the capital stock and equity interests of its subsidiaries). The Term Loan is repayable in quarterly installments on the last business day of each fiscal quarter, beginning December 31, 2023, in an amount equivalent to 1.25 %, of the original principal amount. The outstanding unpaid principal amount and all accrued but unpaid interest thereon, shall be due and payable on the earlier of (i) the fourth anniversary of the closing date of the Term Loan or (ii) the date on which the Term Loan is declared due and payable pursuant to the terms of the Financing. The Company may prepay, subject to an Applicable Premium, 3 % if the prepayment is made on a date that is up to and including the first anniversary of closing, 2 %, if the prepayment is made up to and including the second anniversary, 1 % if the prepayment is made up to and including the third anniversary and zero thereafter, all or a portion of the Term Loan and, under certain circumstances, including certain asset disposals and the raising of indebtedness not permitted under the Term Loan is required to make mandatory prepayments of the principal balance. If the prepayment occurs within 12 months of the date of the loan, the Company is also required to pay lost interest from the prepayment date to one year from the loan funding date. In addition, the Company is required to make a mandatory prepayment on March 31, of each year, commencing with 2025, equivalent to Excess Cash Flow multiplied by a percentage factor of 25%, if the leverage ratio is 3.60 to 1.00 or less, 50% if the leverage ratio is greater than 3.60 to 1 or less than or equal; to 4.10 to 1.00 and 75%, if the leverage ratio is greater than 4.10 to 1.00. Excess Cash Flow is defined in the Financing Agreement as Consolidated EBITDA for the previous fiscal year less scheduled principal and interest payments, capital expenditure, cash taxes and any cash expenses/gains added back to net income in the calculation of Consolidated EBITDA, adjusted for any increase/decrease in working capital during the fiscal year. During the year ended December 31, 2024, the Company made total principal repayments of $ 4.0 million, including a voluntary prepayment of $ 2.0 million. During the year ended December 31, 2023, the Company made total principal repayments of $ 1.7 million, including a mandatory prepayment of $ 1.2 million as a result of an asset sale completed during the year. At the Company’s option the Term Loan, or any portion thereof bears interest at either: a. The greater of (a) 4.00 % per annum, (b) the Federal Funds Rate plus 0.50 % per annum, (c) the one month Secured Overnight Financing Rate (“SOFR”), plus an adjustment of 26.161 basis point and 1.00 % per annum, and (d) the rate last quoted by The Wall Street Journal as the “Prime Rate”, plus an Applicable Margin of 7.5 %; or b. Three-month SOFR plus an adjustment of 26.161 basis points and an Applicable Margin of 8.5 % As of December 31, 2024, the Loan bears interest at 13.3 % per annum, with the effective interest rate for the year ended December 31, 2024, including the amortization of debt issuance costs and Applicable Premium and interest penalties of $ 66,804 associated with the prepayment during the year ended December 31, 2024 was 16.5 %. F- 29 OPTIMIZERx CORPORATION NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (in thousands, excepts share and per share data) The Term Loan requires the Company to maintain certain maximum leverage ratios and Liquidity (as defined in the Financing Agreement), of at least $ 5.0 million. The Company was in compliance with its financial covenants as of December 31, 2024. The Term Loan contains customary events of default, which include, (subject to, in certain circumstances to grace and cure periods), non-payment of principal and interest, non-compliance with certain covenants, commencement of bankruptcy proceedings and a change in control. Payments due on the Term Loan in each of the next three years subsequent to December 31, 2024, are as follows: For the year ending December 31, 2025 2,000 2026 2,000 2027 30,290 $ 34,290 NOTE 13 – LEASES In February 2016, the FASB issued new accounting guidance on leases. The accounting standard, effective January 1, 2019, requires virtually all leases to be recognized on the balance sheet. Under the guidance, we have elected not to separate lease and non-lease components in recognition of the lease-related assets and liabilities, as well as the related lease expense. We had operating leases with terms greater than 12 months for office space in four multi-tenant facilities, which are recorded as ROU assets and Operating lease liabilities. For the years ended December 31, 2024 and 2023, the Company’s lease cost consisted of the following components, each of which is included in operating expenses within the Company’s consolidated statements of operations: 2024 2023 Operating lease cost $ 248 $ 96 Short-term lease cost (1) 2 39 Total lease cost $ 250 $ 135 (1) Short-term lease cost includes any lease with a term of less than 12 months. The table below presents the future minimum lease payments to be made under operating leases as of December 31, 2024: For the year ending December 31, 2025 $ 188 2026 115 2027 67 2028 45 2029 — Total 415 Less: present value discount 38 Total lease liabilities $ 377 F- 30 OPTIMIZERx CORPORATION NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (in thousands, excepts share and per share data) The weighted average remaining lease term for operating leases is 2.65 and the weighted average discount rate used in calculating the operating lease asset and liability is 7.1 %. Cash paid for amounts included in the measurement of lease liabilities was $ 227 . For the year ended December 31, 2024, payments on lease obligations were $ 260 and amortization on the right of use assets was $ 237 . For the year ended December 31, 2023, payments on lease obligations were $ 91 and amortization on the right of use assets was $ 95 . NOTE 14 – MAJOR CUSTOMERS AND VENDORS The Company had the following customers that accounted for 10% or greater of revenue in either 2024 or 2023. No other customers accounted for more than 10% of revenue in either year presented. 2024 2023 $ % $ % Customer A 15,556 16.9 5,825 8.1 Customer B 12,760 13.9 10,275 14.4 Our accounts receivable included three agencies, that represented multiple customers, that individually made up more than 10% of our accounts receivable at December 31, 2024 in the percentages of 32.0 %, 21.1 % and 11.2 %. As of December 31, 2023, our accounts receivable included two agencies, that represented multiple customers, that individually made up more than 10% of our accounts receivable in the percentages of 28.3 % and 14.1 %. The Company generates a portion of its revenues through its EHR and eRx channel partners. There were three key channel partners and/or vendors through which 10% or greater of its revenue was generated in either 2024 or 2023 as set forth below. The amounts in the table below reflect the amount of revenue generated through those channel partners. 2024 2023 $ % $ % Partner A 26,815 29.1 26,035 36.4 Partner B 25,978 28.2 13,955 19.5 Partner C 10,999 11.9 * * * Less than 10% of revenue NOTE 15 – INCOME TAXES As of December 31, 2024, the Company had net operating loss (“NOLs”) carry-forwards for federal income tax purposes of approximately $ 11.6 million, consisting of post-2017 losses that will never expire. These net operating losses are available to offset future taxable income. The Company was formed in 2008 as a Nevada Corporation. Activity prior to incorporation is not reflected in the Company’s corporate tax returns. In the future, the cumulative net operating loss carry-forward for income tax purposes may differ from the cumulative financial statement loss due to timing differences between book and tax reporting. F- 31 OPTIMIZERx CORPORATION NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (in thousands, excepts share and per share data) The provision for Federal income tax consists of the following for the years ended December 31, 2024 and 2023: 2024 2023 Federal income tax benefit (expense) attributable to: Current operations $ 4,071 $ 5,284 State tax effect, net of federal benefit 696 569 Option exercise benefits (expenses), net of Section 162M limitations ( 480 ) ( 476 ) Transaction costs — ( 360 ) Goodwill impairment ( 1,413 ) — Stock compensation ( 2,531 ) ( 2,624 ) Other adjustments ( 204 ) 45 Valuation allowance ( 864 ) 5,160 Income tax (expense) benefit $ ( 725 ) $ 7,598 2024 2023 Current tax benefit (expense) - Federal $ ( 258 ) $ — Current tax benefit (expense) - State ( 314 ) ( 97 ) Total current (expense) ( 572 ) ( 97 ) Deferred tax (expense) benefit - Federal ( 96 ) 6,489 Deferred tax (expense) benefit - State ( 57 ) 1,206 Total deferred (expense) benefit ( 153 ) 7,695 Income tax (expense) benefit $ ( 725 ) $ 7,598 The cumulative tax effect of significant items comprising our net deferred tax amount at the expected rate of 21 % is as follows as of December 31, 2024 and 2023: 2024 2023 Deferred tax assets attributable to: Net operating loss carryover $ 3,304 $ 4,864 Stock compensation 3,121 3,744 Operating lease liability 105 115 Section 174 capitalized expenses 3,091 2,533 Tax credits 355 361 Goodwill 171 103 Section 163 (J) interest limitation 967 — Other 559 — Deferred tax assets $ 11,673 $ 11,720 Deferred tax liabilities attributable to: Intangibles $ ( 11,760 ) $ ( 12,393 ) Operating lease right-of-use assets ( 102 ) ( 110 ) Other ( 82 ) ( 198 ) Deferred tax liabilities ( 11,944 ) ( 12,701 ) Net deferred tax (liability) asset $ ( 271 ) $ ( 981 ) Valuation allowance ( 4,220 ) ( 3,356 ) Net deferred tax liabilities $ ( 4,491 ) $ ( 4,337 ) F- 32 OPTIMIZERx CORPORATION NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (in thousands, excepts share and per share data) The ultimate realization of deferred tax assets is dependent upon the Company’s ability to generate sufficient taxable income during the periods in which the net operating losses expire and the temporary differences become deductible. The Company has determined that there is significant uncertainty that the results of future operations and the reversals of existing taxable temporary differences will generate sufficient taxable income to realize the deferred tax assets; therefore, a valuation allowance has been recorded. In making this determination, the Company considered historical levels of income, projections for future periods, and the significant amount of tax deductions to be generated from the future exercise of stock options. The tax years 2021 to 2024 remain open for potential audit by the Internal Revenue Service. There are no uncertain tax positions as of December 31, 2023 or December 31, 2024, and none are expected in the next 12 months. The Company’s foreign subsidiaries are cost centers that are primarily reimbursed for expenses, as a result they generate an immaterial amount of income or loss. Pretax book income (loss) is all from domestic operations. Up to four years of returns remain open for potential audit in foreign jurisdictions, however any audits for periods prior to ownership by the Company are the responsibility of the previous owners. Under certain circumstances issuance of common shares can result in an ownership change under Internal Revenue Code Section 382, which limits the Company’s ability to utilize carry-forwards from prior to the ownership change. Any such ownership change resulting from stock issuances and redemptions could limit the Company’s ability to utilize any net operating loss carry-forwards or credits generated before this change in ownership. These limitations can limit both the timing of usage of these laws, as well as the loss of the ability to use these net operating losses. The Company had an ownership change as described in IRC Section 382 on March 18, 2014. The Company NOL’s generated up until March 18, 2014 have been fully released. NOTE 16 – COMMITMENTS AND CONTINGENT LIABILITIES Legal From time to time, the Company may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are currently not a party to any material legal or administrative proceedings, and we are not aware of any pending or threatened material legal or administrative proceedings against us. Commitments From time to time, the Company enters into arrangements with channel partners to acquire minimum amounts of media, data or messaging capabilities. As of December 31, 2024, the Company had commitments with channel partners for future minimum payments of $ 19,737 that will be reflected in cost of revenues during the years from 2025 through 2029. Minimum payments are due in 2025, 2026 and 2027 in the amounts of $ 14,396 , $ 3,716 and $ 1,625 , respectively. NOTE 17 – RETIREMENT PLAN The Company sponsors a defined contribution 401(k) profit sharing plan which was adopted in December 2015, effective in January 2016. Under the terms of the plan, the Company matches 100 % of the first 3 % of payroll contributed by the employee and 50 % of the next 2 % of payroll contributed by the employee to a maximum of 4 % of an employee’s payroll. There was expense of $ 837 and $ 727 recorded in 2024 and 2023, respectively, for the Company’s contributions to the plan. NOTE 18 – SUBSEQUENT EVENTS None. F- 33 Item 9. Changes In and Disagreements with Accountants on Accounting and Financial Disclosure None.